Fallopian Tube Cancer Clinical Trials

A listing of 31 Fallopian Tube Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Fallopian Tube Cancer

1 - 12 of 31

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 31 active clinical trials seeking participants for Fallopian Tube Cancer research studies. The states with the highest number of trials for Fallopian Tube Cancer participants are California, England, Texas and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT06906341

Recruiting

This is a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/23/2025

Locations: 014, San Francisco, California +22 locations

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms

Learn More ›

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

NCT06690775

Recruiting

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/20/2025

Locations: SCRI - Arizona Oncology Associates, PC-HOPE, Tucson, Arizona +23 locations

SCRI - Arizona Oncology Associates, PC-HOPE, Tucson, Arizona

City of Hope National Medical Center, Duarte, California

UCLA - JCCC Clinical Research Unit, Los Angeles, California

SCRI - Sansum Clinic, Santa Barbara, California

SCRI - Maryland Oncology Hematology, P.A., Annapolis, Maryland

Massachusetts General Hospital, Boston, Massachusetts

SCRI - Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota

University of Minnesota, Minneapolis, Minnesota

Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, Oklahoma

SCRI - Northwest Cancer Specialists, P.C., Portland, Oregon

SCRI - Alliance Cancer Specialists, PC, Doylestown, Pennsylvania

University of Pennsylvania, Philadelphia, Pennsylvania

SCRI - Texas Oncology, Fort Worth, Texas

SCRI - Virginia Oncology Associates, Norfolk, Virginia

Monash Medical Centre, Clayton, Melbourne

Icon Cancer Centre Chermside, Chermside, Queensland

Linear Clinical Research, Perth, Western Australia

British Columbia Cancer Agency (BC Cancer, part of the Provincial Health Services Authority), Vancouver, British Columbia

Sunnybrook Health Sciences Centre, Toronto, Ontario

Princess Margaret Cancer Centre - University Health Network (UHN), Toronto, Ontario

Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec

Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec

McGill University Health Centre (MUHC) - Royal Victoria Hospital, Montreal, Quebec

National University Hospital, Singapore, Not set

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer

Learn More ›

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467

Recruiting

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/20/2025

Locations: Sarasota Memorial Hospital ( Site 0075), Sarasota, Florida +27 locations

Sarasota Memorial Hospital ( Site 0075), Sarasota, Florida

St. Dominic's Hospital ( Site 0064), Jackson, Mississippi

Nebraska Methodist Hospital ( Site 0053), Omaha, Nebraska

Rutgers Cancer Institute of New Jersey ( Site 0071), New Brunswick, New Jersey

University of Cincinnati Medical Center ( Site 0090), Cincinnati, Ohio

Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056), Tulsa, Oklahoma

Women & Infants Hospital ( Site 0050), Providence, Rhode Island

Gallipoli Medical Research Ltd ( Site 0214), Brisbane, Queensland

Epworth Freemasons ( Site 0217), East Melbourne, Victoria

Kurume University Hospital ( Site 1640), Kurume, Fukuoka

Saitama Medical University International Medical Center ( Site 1632), Hidaka, Saitama

Cancer Institute Hospital of JFCR ( Site 1639), Koto, Tokyo

Keio University Hospital ( Site 1636), Shinjyuku, Tokyo

Niigata Cancer Center Hospital ( Site 1633), Niigata, Not set

National Cancer Center ( Site 2305), Goyang-si, Kyonggi-do

Severance Hospital ( Site 2302), Seodaemun-Gu, Seoul

Asan Medical Center ( Site 2304), Songpa-gu, Seoul

Seoul National University Hospital ( Site 2301), Seoul, Not set

Samsung Medical Center ( Site 2303), Seoul, Not set

Institut Català d'Oncologia (ICO) - Girona ( Site 2402), Girona, Gerona

Clinica Universidad de Navarra ( Site 2407), Madrid, Madrid, Comunidad De

Hospital Vall D Hebron ( Site 2403), Barcelona, Not set

ICO L Hospitalet ( Site 2408), Barcelona, Not set

Hospital Universitario Reina Sofia ( Site 2406), Cordoba, Not set

Hospital Ramon y Cajal ( Site 2405), Madrid, Not set

Taichung Veterans General Hospital ( Site 2603), Taichung, Not set

National Cheng Kung University Hospital ( Site 2602), Tainan, Not set

Mackay Memorial Hospital ( Site 2604), Taipei, Not set

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Learn More ›

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

NCT05527184

Recruiting

IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/20/2025

Locations: University of Alabama at Birmingham /ID# 269045, Birmingham, Alabama +28 locations

University of Alabama at Birmingham /ID# 269045, Birmingham, Alabama

City of Hope National Medical Center /ID# 269036, Duarte, California

Moores Cancer Center /ID# 269040, La Jolla, California

University of California Los Angeles Medical Center /ID# 269037, Los Angeles, California

Hoag Memorial Hospital Presbyterian /ID# 269047, Newport Beach, California

UCHSC Anschultz Cancer Pavilion /ID# 269056, Aurora, Colorado

AdventHealth Celebration /ID# 269030, Kissimmee, Florida

Mount Sinai Medical Center /ID# 269050, Miami, Florida

Miami Cancer Institute at Baptist Health /ID# 269041, Miami, Florida

Florida Cancer Specialists- Sarasota Cattlemen /ID# 269055, Sarasota, Florida

University of Chicago Medical Center /ID# 269028, Chicago, Illinois

Dana-Farber Cancer Institute /ID# 269039, Boston, Massachusetts

Karmanos Cancer Institute - Detroit /ID# 269052, Detroit, Michigan

University of Mississippi Medical Cancer Center /ID# 269046, Jackson, Mississippi

Washington University School of Medicine - St. Louis /ID# 269048, Saint Louis, Missouri

Holy Name Medical Center /ID# 269051, Teaneck, New Jersey

Roswell Park Cancer Institute /ID# 269043, Buffalo, New York

Long Island Jewish Medical Center /ID# 269035, New Hyde Park, New York

Columbia University Irving Medical Center /ID# 269033, New York, New York

University of North Carolina Medical Center /ID# 269027, Chapel Hill, North Carolina

The Ohio State University Comprehensive Cancer Center /ID# 269026, Columbus, Ohio

Ou Health - Stephenson Cancer Center /ID# 269025, Oklahoma City, Oklahoma

University of Pennsylvania /ID# 269042, Philadelphia, Pennsylvania

West Penn Hospital /ID# 269054, Pittsburgh, Pennsylvania

Women & Infants Hospital /ID# 269032, Providence, Rhode Island

Tennessee Oncology Nashville /ID# 269029, Nashville, Tennessee

MD Anderson Houston /ID# 269057, Houston, Texas

University of Virginia /ID# 269053, Charlottesville, Virginia

BC Cancer - Kelowna /ID# 268983, Kelowna, British Columbia

Conditions: Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer

Learn More ›

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778

Recruiting

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/17/2025

Locations: Usa Mitchell Cancer Institute /ID# 269661, Mobile, Alabama +239 locations

Usa Mitchell Cancer Institute /ID# 269661, Mobile, Alabama

Honorhealth Virginia G. Piper Cancer Care Network - Biltmore /ID# 269987, Phoenix, Arizona

City of Hope Orange County Lennar Foundation Cancer Center /ID# 269573, Irvine, California

Moores Cancer Center at UC San Diego /ID# 269564, La Jolla, California

University Of California Irvine Medical Center /ID# 269572, Orange, California

Stanford Women'S Cancer Center /ID# 269552, Palo Alto, California

Kaiser Permanente Zion Medical Center /ID# 269537, San Diego, California

Kaiser Permanente - San Diego Medical Center /ID# 269540, San Diego, California

Kaiser Permanente - San Marcos Medical Offices /ID# 269542, San Marcos, California

Olive View-Ucla Medical Center /ID# 269584, Sylmar, California

John Muir Health - Walnut Creek Medical Center /ID# 269575, Walnut Creek, California

Broward General Medical Center /ID# 269577, Fort Lauderdale, Florida

Regional Cancer Center /ID# 269558, Fort Myers, Florida

Baptist Md Anderson Cancer Center - Jacksonville - Palm Avenue /ID# 269560, Jacksonville, Florida

Mount Sinai Medical Center /ID# 269582, Miami, Florida

Sarasota Memorial Hospital /ID# 269526, Sarasota, Florida

Northside Hospital /ID# 269660, Atlanta, Georgia

Rush University Medical Center /ID# 269583, Chicago, Illinois

University of Chicago Medical Center /ID# 269546, Chicago, Illinois

Indiana University Melvin and Bren Simon Comprehensive Cancer Center /ID# 269110, Indianapolis, Indiana

St. Vincent Indianapolis Hospital /ID# 269107, Indianapolis, Indiana

University of Iowa /ID# 269566, Iowa City, Iowa

The University of Kansas Cancer Center - Westwood /ID# 269106, Westwood, Kansas

Baptist Health Lexington /ID# 269568, Lexington, Kentucky

University of Kentucky Chandler Medical Center /ID# 269536, Lexington, Kentucky

Louisiana State University Health Sciences Center - New Orleans /ID# 269559, New Orleans, Louisiana

Ochsner Medical Center - Jefferson Highway /ID# 269530, New Orleans, Louisiana

Maine Medical Center - Scarborough Campus /ID# 269555, Scarborough, Maine

Johns Hopkins Hospital /ID# 269579, Baltimore, Maryland

Sinai Hospital Of Baltimore /ID# 269567, Manchester, Maryland

GBMC Cancer Center /ID# 269561, Towson, Maryland

Tufts Medical Center /ID# 269547, Boston, Massachusetts

Baystate Medical Center /ID# 269544, Springfield, Massachusetts

Corewell Health /ID# 269562, Grand Rapids, Michigan

Minnesota Oncology - Coon Rapids Clinic /ID# 269550, Coon Rapids, Minnesota

Nebraska Methodist Hospital /ID# 269580, Omaha, Nebraska

The Center Of Hope /ID# 269528, Reno, Nevada

Dartmouth-Hitchcock Medical Center - 1 Medical Center Drive /ID# 269576, Lebanon, New Hampshire

John Theurer Cancer Center /ID# 269109, Hackensack, New Jersey

The Valley Hospital /ID# 269548, Paramus, New Jersey

Holy Name Medical Center /ID# 269543, Teaneck, New Jersey

New York Oncology Hematology - Albany Cancer Center /ID# 269565, Albany, New York

Women'S Cancer Care Associates /ID# 269553, Albany, New York

Northwell Health Center for Advanced Medicine /ID# 269108, Lake Success, New York

NYU Laura and Isaac Perlmutter Cancer Center /ID# 269556, New York, New York

Icahn School of Medicine at Mount Sinai /ID# 269529, New York, New York

University of North Carolina at Chapel Hill /ID# 269563, Chapel Hill, North Carolina

Duke Cancer Institute /ID# 269557, Durham, North Carolina

University of Cincinnati /ID# 269578, Cincinnati, Ohio

The Ohio State University Comprehensive Cancer Center /ID# 269105, Columbus, Ohio

Kettering Medical Center /ID# 269585, Kettering, Ohio

Ou Health - Stephenson Cancer Center /ID# 269525, Oklahoma City, Oklahoma

Oklahoma Cancer Specialists and Research Institute /ID# 269527, Tulsa, Oklahoma

Willamette Valley Cancer Institute and Research Center /ID# 269988, Eugene, Oregon

Compass Oncology - Rose Quarter /ID# 270131, Portland, Oregon

Oregon Health and Science University /ID# 269581, Portland, Oregon

Magee-Womens Hospital of UPMC /ID# 269659, Pittsburgh, Pennsylvania

Allegheny Health Network West Penn Hospital /ID# 269551, Pittsburgh, Pennsylvania

Asplundh Cancer Pavilion /ID# 269574, Willow Grove, Pennsylvania

Sanford Cancer Center /ID# 269535, Sioux Falls, South Dakota

West Cancer Center and Research Institute - Germantown /ID# 269569, Germantown, Tennessee

Texas Oncology - Austin Central /ID# 269531, Austin, Texas

Texas Oncology - Bedford /ID# 269571, Bedford, Texas

Texas Oncology - Methodist Dallas Cancer Center /ID# 269554, Dallas, Texas

Texas Oncology - Fort Worth Cancer Center /ID# 269532, Fort Worth, Texas

Texas Oncology, P. A. /ID# 269549, San Antonio, Texas

University of Virginia Health System /ID# 269545, Charlottesville, Virginia

Virginia Oncology Associates - Norfolk (Lake Wright) /ID# 269533, Norfolk, Virginia

Vcu Health Adult Outpatient Pavillion /ID# 269570, Richmond, Virginia

Swedish Cancer Institute /ID# 269538, Seattle, Washington

Sanatorio De La Mujer /ID# 269352, Rosario, Santa Fe

Hospital Italiano de Buenos Aires /ID# 269356, Buenos Aires, Not set

Sociedad de Beneficiencia Hospital Italiano /ID# 269090, Cordoba, Not set

Isis Centro Especializado De Luce /ID# 269353, Santa Fe, Not set

Westmead Hospital /ID# 269362, Westmead, New South Wales

Gold Coast University Hospital /ID# 269365, Southport, Queensland

Ballarat Base Hospital /ID# 269364, Ballarat, Victoria

Monash Health - Monash Medical Centre /ID# 269360, Clayton, Victoria

Cabrini Hospital - Malvern /ID# 269359, Malvern, Victoria

Peter MacCallum Cancer Centre /ID# 269361, Melbourne, Victoria

Epworth Hospital /ID# 269363, Richmond, Victoria

St. John Of God Subiaco Hospital /ID# 269358, Subiaco, Western Australia

Imelda Ziekenhuis /ID# 269369, Bonheiden, Antwerpen

Cliniques Universitaires UCL Saint-Luc /ID# 269368, Bruxelles, Bruxelles-Capitale

Grand Hôpital De Charleroi - Notre Dame /ID# 269367, Charleroi, Hainaut

AZ Sint-Lucas /ID# 269366, Gent, Oost-Vlaanderen

Universitair Ziekenhuis Leuven /ID# 269370, Leuven, Vlaams-Brabant

AZ-Delta /ID# 269091, Roeselare, West-Vlaanderen

UCL Namur University Hospital, Site Sainte-Elisabeth /ID# 269371, Namur, Not set

Complex Oncology Center - Shumen /ID# 269372, Shumen, Not set

Comprehensive Cancer Center /ID# 269373, Vratsa, Not set

Arthur J. E. Child Comprehensive Cancer Centre /ID# 269388, Calgary, Alberta

Cross Cancer Institute /ID# 269392, Edmonton, Alberta

Bc Cancer Agency - Fraser Valley Centre /ID# 269398, Surrey, British Columbia

BC Cancer - Vancouver /ID# 269394, Vancouver, British Columbia

Juravinski Cancer Centre - Hamilton Health Sciences /ID# 269396, Hamilton, Ontario

Kingston General Hospital /ID# 269397, Kingston, Ontario

The Ottawa Hospital - General Campus /ID# 269391, Ottawa, Ontario

Princess Margaret Cancer Centre /ID# 269390, Toronto, Ontario

Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 269395, Montreal, Quebec

CHUM - Centre hospitalier de l'Universite de Montréal /ID# 269387, Montreal, Quebec

McGill University Health Centre /ID# 269389, Montreal, Quebec

CIUSSS Estrie - Sherbrooke University Hospital Center /ID# 269393, Sherbrooke, Quebec

The first affiliated hospital of bengbu medical college, Bengbu, Anhui

Capital Medical University (Cmu), Beijing, Beijing

Beijing Cancer Hospital, Beijing, Beijing

Fujian Province Cancer Hospital, Fuzhou, Fujian

The First Affiliated Hospital, Sun-Yat Sen University, Guangzhou, Guangdong

Sun Yat-Sen University (Sysu) - Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong

Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

Henan Cancer Hospital, Zhengzhou, Henan

The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan

Hubei Cancer Hospital, Wuhan, Hubei

Hunan Province Cancer Hospital, Changsha, Hunan

The First Bethune Hospital Of Jilin University, Changchun, Jilin

Liaoning Cancer Hospital & Institute, Shenyang, Liaoning

The First Affiliated Hospital of Xi'an Jiaotong University, Xian, Shaanxi

Qilu Hospital Of Shandong University, Jinan, Shandong

Shandong Cancer Hospital, Jinan, Shandong

LinYi Cancer Hospital, Linyi, Shandong

Fudan University Cancer Hospital, Shanghai, Shanghai

Shanxi Cancer Hospital, Taiyuan, Shanxi

West China Second University Hospital, Sichuan University, Chengdu, Sichuan

Tianjin Cancer Hospital, Tianjin, Tianjin

Cancer Hospital Affliated to Xinjiang Medical University, Urumqi, Xinjiang

Yunnan Province Cancer Hospital, Kunming, Yunnan

The Affiliated Women's Hospital Of Zhejiang University, Hangzhou, Zhejiang

Zhejiang Cancer Hospital, Hangzhou, Zhejiang

Fakultní Nemocnice Brno - Jihlavská /ID# 269401, Brno, Brno-mesto

General University Hospital in Prague, Charles University /ID# 269402, Prague, Ceske Budejovice

Nemocnice Novy Jicin /ID# 269400, Nový Jičín, Novy Jicin

Fakultní nemocnice Ostrava /ID# 269403, Ostrava, Ostrava-mesto

Hôpital La Timone /ID# 269421, Marseille, Bouches-du-Rhone

Chu Dijon /Id# 269417, Dijon, Bourgogne-Franche-Comte

CHU Brest /ID# 269422, Brest, Finistere

Centre Leon Berard /ID# 269418, Lyon CEDEX 08, Rhone

Institut Curie /ID# 269420, Paris, Not set

Institut de cancérologie Strasbourg Europe (ICANS) /ID# 269419, Strasbourg, Not set

Klinikum Esslingen /ID# 269435, Esslingen am Neckar, Baden-Wuerttemberg

Universitaetsklinikum Erlangen /ID# 269439, Erlangen, Bayern

Universitaetsklinikum Bonn /ID# 269434, Bonn, Nordrhein-Westfalen

Klinikum Dortmund Klinikzentrum Mitte /ID# 269441, Dortmund, Nordrhein-Westfalen

Universitaetsklinikum Carl Gustav Carus Dresden /ID# 269433, Dresden, Sachsen

Universitätsklinikum Gießen /ID# 269432, Giessen, Not set

Krankenhaus Jerusalem /ID# 269430, Hamburg, Not set

St. Luke's Hospital S.A. /ID# 269445, Panorama, Thessaloniki

General Hospital of Athens Alexandra /ID# 269444, Athens, Not set

Hygeia Hospital /ID# 270132, Athens, Not set

IASO Hospital /ID# 269443, Marousi, Not set

St James Hospital /ID# 269446, Dublin 8, Dublin

Bon Secours Cork Hospital /ID# 269449, Cork, Not set

Cork University Hospital /ID# 269451, Cork, Not set

Beaumont Hospital /ID# 269452, Dublin, Not set

University Hospital Galway /ID# 269447, Galway, Not set

Sligo General Hospital /ID# 269448, Sligo, Not set

Waterford Regional Hospital /ID# 269450, Waterford, Not set

The Lady Davis Carmel Medical Center /ID# 269453, Haifa, H_efa

Edith Wolfson Medical Center /ID# 269461, Holon, HaMerkaz

Meir Medical Center /ID# 269454, Kfar Saba, HaMerkaz

Rabin Medical Center /ID# 269456, Petah Tikva, HaMerkaz

Kaplan Medical Center /ID# 269457, Rekhovot, HaMerkaz

The Chaim Sheba Medical Center /ID# 269094, Ramat Gan, Tel-Aviv

Tel Aviv Sourasky Medical Center /ID# 269455, Tel Aviv, Tel-Aviv

Shaare Zedek Medical Center /ID# 269459, Jerusalem, Not set

Hadassah Medical Center-Hebrew University /ID# 269458, Jerusalem, Not set

ZIV Medical Center /ID# 269460, Safed, Not set

Azienda Ospedaliero Universitaria Careggi /ID# 269465, Florence, Firenze

Ente Ospedaliero Ospedali Galliera /ID# 269472, Genoa, Genova

Ospedale San Martino /ID# 269469, Genoa, Genova

IRCCS Istituto Clinico Humanitas /ID# 269473, Rozzano, Lombardia

IRCCS Ospedale San Raffaele /ID# 269475, Milan, Milano

Istituto Nazionale Dei Tumori /ID# 269477, Milan, Milano

Istituto Nazionale Tumori Irccs Fondazione G. Pascale /ID# 269097, Naples, Napoli

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 269474, Meldola, Reggio Emilia

Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 269470, Rome, Roma

Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 269096, Rome, Roma

Ospedale di Mirano - Azienda ULSS 3 /ID# 269462, Mirano, Venezia

IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 269476, Bologna, Not set

Ospedale Cannizzaro /ID# 269478, Catania, Not set

Alessandro Manzoni Hospital /ID# 269467, Lecco, Not set

Azienda USL Toscana Nord Ovest - Ospedale San Luca /ID# 269095, Lucca, Not set

Azienda Ospedaliero Universitaria Di Parma /ID# 269466, Parma, Not set

Fondazione IRCCS Policlinico San Matteo /ID# 269463, Pavia, Not set

AUSL Piacenza-Ospedale Guglielmo da Saliceto /ID# 269468, Piacenza, Not set

New Hospital of Prato - S. Stefano /ID# 269464, Prato, Not set

AUSL di Reggio Emilia - Arcispedale Santa Maria Nuova /ID# 269471, Reggio Emilia, Not set

Aichi Cancer Center /ID# 274332, Nagoya-shi, Aichi

Chiba University Hospital /ID# 274371, Chiba-shi, Chiba

National Hospital Organization Shikoku Cancer Center /ID# 276078, Matsuyama, Ehime

Kurume University Hospital /ID# 274337, Kurume-shi, Fukuoka

Hokkaido University Hospital /ID# 274331, Sapporo-shi, Hokkaido

Sapporo Medical University Hospital /ID# 274330, Sapporo, Hokkaido

Hyogo Cancer Center /ID# 274323, Akashi-shi, Hyogo

Iwate Medical University Hospital - Yahabacho /ID# 274635, Yahaba, Iwate

Tokai University Hospital /ID# 274336, Isehara, Kanagawa

Tohoku University Hospital /ID# 274327, Sendai-shi, Miyagi

Niigata University Medical & Dental Hospital /ID# 274329, Niigata-shi, Niigata

Okayama University Hospital /ID# 274324, Okayama-shi, Okayama

Saitama Medical University International Medical Center /ID# 274953, Hidaka, Saitama

Shizuoka Cancer Center /ID# 274325, Sunto-gun, Shizuoka

National Cancer Center Hospital /ID# 274321, Chuo-Ku, Tokyo

The Cancer Institute Hospital Of JFCR /ID# 274326, Koto-ku, Tokyo

The Jikei University Hospital /ID# 276160, Minato-ku, Tokyo

Keio University Hospital /ID# 276159, Shinjuku-ku, Tokyo

National Cancer Center /ID# 269481, Goyang-si, Gyeonggido

Seoul National University Bundang Hospital /ID# 269482, Seongnam-si, Gyeonggido

CHA Bundang Medical Center /ID# 269489, Seongnam, Gyeonggido

Keimyung University Dongsan Hospital /ID# 269488, Daegu, Gyeongsangbugdo

Korea University Anam Hospital /ID# 269486, Seoul, Seoul Teugbyeolsi

Seoul National University Hospital /ID# 269479, Seoul, Seoul Teugbyeolsi

Yonsei University Health System Severance Hospital /ID# 269483, Seoul, Seoul Teugbyeolsi

Asan Medical Center /ID# 269480, Seoul, Seoul Teugbyeolsi

Gangnam Severance Hospital /ID# 269484, Seoul, Seoul Teugbyeolsi

Samsung Medical Center /ID# 269487, Seoul, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St. Marys Hospital /ID# 269485, Seoul, Seoul Teugbyeolsi

Korea University Guro Hospital /ID# 269490, Seoul, Seoul Teugbyeolsi

The Medical City /ID# 269493, Pasig, National Capital Region

East Avenue Medical Center /ID# 269099, Quezon City, National Capital Region

Cardinal Santos Medical Center /ID# 269100, San Juan City, National Capital Region

Mazowiecki Szpital Wojewodzki im. Sw. Jana Pawla II w Siedlcach Sp. z o.o. /ID# 269500, Siedlce, Mazowieckie

Szpitale Pomorskie Sp. z o.o. /ID# 269495, Gdynia, Pomorskie

Complejo Hospitalario Universitario A Coruña /ID# 269414, A Coruña, A Coruna

Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 269409, L'Hospitalet de Llobregat, Barcelona

Clinica Universidad de Navarra - Pamplona /ID# 269410, Pamplona, Navarra

Hospital Universitari Vall d'Hebron /ID# 269406, Barcelona, Not set

Hospital Clinic de Barcelona /ID# 269408, Barcelona, Not set

Hospital Universitari De Girona Doctor Josep Trueta /ID# 269411, Girona, Not set

CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 269405, Madrid, Not set

Hospital Universitario La Paz /ID# 269407, Madrid, Not set

Hospital Clínico Universitario de Valencia /ID# 269412, Valencia, Not set

Hacettepe University Faculty of Medicine /ID# 269521, Ankara, Not set

Cheltenham General Hospital /ID# 269427, Cheltenham, Gloucestershire

Guy's Hospital /ID# 269426, London, Greater London

The Royal Marsden - Chelsea /ID# 269102, London, Greater London

Mount Vernon Hospital /ID# 269423, Northwood, Greater London

University Hospital Southampton /ID# 269425, Southampton, Hampshire

The Royal Marsden - Sutton /ID# 269103, Sutton, Surrey

The Christie /ID# 269428, Manchester, Not set

Singleton Hospital /ID# 269424, Swansea, Not set

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

Learn More ›

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

NCT05071937

Recruiting

This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/17/2025

Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

Learn More ›

A Study of XMT-1660 in Participants With Solid Tumors

NCT05377996

Recruiting

A Study of XMT-1660 in Solid Tumors

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/13/2025

Locations: UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California +21 locations

Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma

Learn More ›

Using Aspirin to Improve Immunological Features of Ovarian Tumors

NCT05080946

Recruiting

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/11/2025

Locations: Moffitt Cancer Center, Tampa, Florida +3 locations

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Learn More ›

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068

Recruiting

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/05/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +66 locations

University of Alabama at Birmingham, Birmingham, Alabama

University of Arkansas - Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas

USC Norris Comprehensive Cancer Center, Los Angeles, California

Sansum Clinic, Santa Barbara, California

Providence Medical Foundation, Santa Rosa, California

Rocky Mountain Cancer Center, Denver, Colorado

Sarah Cannon Research Institute at HealthONE, Denver, Colorado

Florida Cancer Specialists, Fort Myers, Florida

Cancer Specialists of North Florida, Jacksonville, Florida

Florida Cancer Specialists, Orlando, Florida

Florida Cancer Specialists, Sarasota, Florida

Florida Cancer Specialists, West Palm Beach, Florida

Hope and Healing Cancer Services, Hinsdale, Illinois

Community Health Network, Indianapolis, Indiana

Our Lady of the Lake, Baton Rouge, Louisiana

Maryland Oncology Hematology - Primary, Columbia, Maryland

Minnesota Oncology Hematology, Maple Grove, Minnesota

Washington University, Saint Louis, Missouri

Hematology Oncology Associates of Central New York, East Syracuse, New York

Oncology Hematology Care Primary, Cincinnati, Ohio

Taylor Cancer Research Center, Maumee, Ohio

Oklahoma University, Oklahoma City, Oklahoma

Stephenson Cancer Center, Oklahoma City, Oklahoma

Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia, Pennsylvania

Tennessee Oncology, PLLC, Chattanooga, Tennessee

Baptist Cancer Center, Memphis, Tennessee

SCRI Oncology Partners, Nashville, Tennessee

Texas Oncology - Central/South Texas, Austin, Texas

Mary Crowley Cancer Research, Dallas, Texas

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

Texas Oncology - Northeast Texas, Flower Mound, Texas

Oncology Consultants, Houston, Texas

Texas Oncology - San Antonio, San Antonio, Texas

Utah Cancer Specialists, Salt Lake City, Utah

Virginia Cancer Specialists, Fairfax, Virginia

Institut Gustave Roussy, Villejuif, Cedex

Institut Bergonie, Bordeau, Not set

Hospital General Universitario de Elche, Elche, Alicante

H. Parc Tauli, Sabadell, Barcelona

Hospital Arnau de Vilanova, Lleida, Catalonia

Next Oncology Barcelona, IOB, Barcelona, Cataluna

Hospital Universitario La Paz, Madrid, Comunidad De Madrid

Next - Hospital Quironsalud Madrid, Pozuelo De Alarcón, Comunidad De Madrid

Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia

Clínica Universidad de Navarra, Madrid, Planta -2

Hospital Teresa Herrera (CHUAC), A Coruña, Not set

Institut Català d'Oncologia Badalona - Hospital Germans Trias i Pujol, Badalona, Not set

Vall d'Hebron Institute of Oncology (VIHO), Barcelona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

ICO Hospitalet, Barcelona, Not set

Hospital Universitario Reina Sofia de Córdoba, Córdoba, Not set

Hospital Universitari Doctor Josep Trueta- ICO de Girona, Girona, Not set

Hospital General Universitario Gregorio Marañón, Madrid, Not set

MD Anderson Cancer Center (Madrid, Madrid, Not set

Hospital Clinico San Carlos, Madrid, Not set

START Madrid Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

START Madrid (Hospital San Chinarro), Madrid, Not set

Hospital Universitario Virgen de la Victoria, Malaga, Not set

Hospital Universitario Virgen de la Victoria, Málaga, Not set

Hospital Virgen Macarena, Sevilla, Not set

Hospital Virgen del Rocío, Sevilla, Not set

Incliva Biomedical Research Institute, University of Valencia, Valencia, Not set

Hospital Universitario Miguel Servet, Zaragoza, Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Guy's and St Thomas' NHS Foundation Trust, London, Not set

Sarah Cannon Research Institute UK, London, Not set

Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, Metastatic Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Acinar Cell Carcinoma

Learn More ›

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05739981

Recruiting

This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/04/2025

Locations: Johns Hopkins Medicine SKCCC, Baltimore, Maryland +2 locations

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Learn More ›

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366

Recruiting

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: USOR HonorHealth, Phoenix, Arizona +36 locations

USOR HonorHealth, Phoenix, Arizona

USOR Arizona Oncology Associates, Tucson, Arizona

University of California Los Angeles Medical Center, Los Angeles, California

University of California, San Diego; Moores Cancer Center, San Diego, California

USOR Sansum Clinic, Santa Barbara, California

Providence Medical Foundation, Santa Rosa, California

USOR Florida Cancer Specialists South, Fort Myers, Florida

USOR Florida Cancer Specialists North, Saint Petersburg, Florida

USOR Florida Cancer Specialists East, West Palm Beach, Florida

University of Kansas Medical Center (KUMC), Westwood, Kansas

USOR Maryland Oncology Hematology, Rockville, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

START Midwest, Grand Rapids, Michigan

USOR Minnesota Oncology Hematology, Maplewood, Minnesota

University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma

USOR Oncology Associates of Oregon, P.C., Eugene, Oregon

Compass Oncology - Rose Quarter, Portland, Oregon

USOR Alliance Cancer Specialist, Doylestown, Pennsylvania

Women and Infants Hospital of Rhode Island, Providence, Rhode Island

Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee

USOR Texas Oncology, Abilene, Texas

Texas Oncology - Central / South Texas, Austin, Texas

Mary Crowley Cancer Research, Dallas, Texas

USOR Texas Oncology, Fort Worth, Texas

Texas Oncology - Northeast TX, Tyler, Texas

USOR Texas Oncology Gulf Coast, Woodland, Texas

START Mountain Region, West Valley City, Utah

USOR Virginia Cancer Specialists, Fairfax, Virginia

USOR Virginia Oncology Associates, Norfolk, Virginia

Cancer hospital, Chinese Academy of Medical Sciences, Beijing, Beijing

Hunan Cancer Hospital - Phase 1, Changsha, Hunan

Hunan Cancer Hospital - Thoracic Medicine Dept II, Changsha, Hunan

Jilin Cancer Hospital, Chang chun, Jilin

Fudan University Shanghai Cancer Center - Gynecologic Oncology, Shanghai, Shanghai

Fudan University Shanghai Cancer Center- Phase 1, Shanghai, Shanghai

Conditions: Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Mesothelioma, Triple Negative Breast Cancer, High Grade Epithelial Ovarian Cancer, Breast Adenocarcinoma, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Serous Ovarian Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Platinum-resistant Ovarian Cancer (PROC), Primary Refractory Ovarian Cancer, Uterine Cancer

Learn More ›

Phase 1 Open-Label Study BL-M17D1 w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

NCT06714617

Recruiting

The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/30/2025

Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +11 locations

Conditions: Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive, HER2 Gene Mutation, Gastroesophageal-junction Cancer, Non Small Cell Lung Cancer, Endometrial Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer, Ovarian Cancer, Urothelial Carcinoma Bladder, Solid Tumor, Adult, Gastric Cancer

Learn More ›

1 - 12 of 31